These evidences suggest that the evaluation of the presence of JAK2 or CSF3R mutations in aCML patients could open the way for specific therapeutic interventions (Fig. 1). The gene discussed is CSF3R; the disease is atypical chronic myeloid leukemia, BCR-ABL1 negative.